KR102751864B1 - 미오스타틴에 결합하는 피브로넥틴 기반 스캐폴드 도메인 단백질 - Google Patents

미오스타틴에 결합하는 피브로넥틴 기반 스캐폴드 도메인 단백질 Download PDF

Info

Publication number
KR102751864B1
KR102751864B1 KR1020227025177A KR20227025177A KR102751864B1 KR 102751864 B1 KR102751864 B1 KR 102751864B1 KR 1020227025177 A KR1020227025177 A KR 1020227025177A KR 20227025177 A KR20227025177 A KR 20227025177A KR 102751864 B1 KR102751864 B1 KR 102751864B1
Authority
KR
South Korea
Prior art keywords
myostatin
amino acid
loop
adnectin
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020227025177A
Other languages
English (en)
Korean (ko)
Other versions
KR20220107082A (ko
Inventor
샤론 클로드
린다 잉글
다사 리포브세크
말라비 마디레디
진저 차오 레이크스트로우
조안나 스웨인
웬준 자오
후이 웨이
아론 피. 얌니우크
비드야산카르 라마무르티
알렉산더 티. 코치히
마틴 제이. 코벳
스탠리 리차드 주니어 크리스텍
Original Assignee
브리스톨-마이어스 스큅 컴퍼니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49253416&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102751864(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 브리스톨-마이어스 스큅 컴퍼니 filed Critical 브리스톨-마이어스 스큅 컴퍼니
Publication of KR20220107082A publication Critical patent/KR20220107082A/ko
Application granted granted Critical
Publication of KR102751864B1 publication Critical patent/KR102751864B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/79—Transferrins, e.g. lactoferrins, ovotransferrins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
KR1020227025177A 2012-09-13 2013-09-12 미오스타틴에 결합하는 피브로넥틴 기반 스캐폴드 도메인 단백질 Active KR102751864B1 (ko)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201261700697P 2012-09-13 2012-09-13
US61/700,697 2012-09-13
US201361780005P 2013-03-13 2013-03-13
US61/780,005 2013-03-13
KR1020207034555A KR102424590B1 (ko) 2012-09-13 2013-09-12 미오스타틴에 결합하는 피브로넥틴 기반 스캐폴드 도메인 단백질
PCT/US2013/059458 WO2014043344A1 (en) 2012-09-13 2013-09-12 Fibronectin based scaffold domain proteins that bind to myostatin

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020207034555A Division KR102424590B1 (ko) 2012-09-13 2013-09-12 미오스타틴에 결합하는 피브로넥틴 기반 스캐폴드 도메인 단백질

Publications (2)

Publication Number Publication Date
KR20220107082A KR20220107082A (ko) 2022-08-01
KR102751864B1 true KR102751864B1 (ko) 2025-01-07

Family

ID=49253416

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020227025177A Active KR102751864B1 (ko) 2012-09-13 2013-09-12 미오스타틴에 결합하는 피브로넥틴 기반 스캐폴드 도메인 단백질
KR1020207034555A Active KR102424590B1 (ko) 2012-09-13 2013-09-12 미오스타틴에 결합하는 피브로넥틴 기반 스캐폴드 도메인 단백질
KR1020157009067A Active KR102187714B1 (ko) 2012-09-13 2013-09-12 미오스타틴에 결합하는 피브로넥틴 기반 스캐폴드 도메인 단백질

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020207034555A Active KR102424590B1 (ko) 2012-09-13 2013-09-12 미오스타틴에 결합하는 피브로넥틴 기반 스캐폴드 도메인 단백질
KR1020157009067A Active KR102187714B1 (ko) 2012-09-13 2013-09-12 미오스타틴에 결합하는 피브로넥틴 기반 스캐폴드 도메인 단백질

Country Status (33)

Country Link
US (9) US8933199B2 (enExample)
EP (4) EP2895503B1 (enExample)
JP (2) JP6346895B2 (enExample)
KR (3) KR102751864B1 (enExample)
CN (2) CN104768969B (enExample)
AU (2) AU2013315482B2 (enExample)
BR (1) BR112015005466B1 (enExample)
CA (1) CA2884730C (enExample)
CL (1) CL2015000500A1 (enExample)
DK (3) DK2895503T3 (enExample)
EA (1) EA033536B1 (enExample)
ES (3) ES2879387T3 (enExample)
FI (1) FI3835310T3 (enExample)
HR (3) HRP20190845T1 (enExample)
HU (3) HUE043482T2 (enExample)
IL (3) IL270110B (enExample)
LT (3) LT2895503T (enExample)
MX (2) MX366666B (enExample)
MY (2) MY189682A (enExample)
NZ (1) NZ628446A (enExample)
PE (1) PE20150954A1 (enExample)
PH (1) PH12015500397B1 (enExample)
PL (3) PL3564258T3 (enExample)
PT (3) PT2895503T (enExample)
RS (3) RS65556B1 (enExample)
SG (3) SG11201501741YA (enExample)
SI (3) SI3835310T1 (enExample)
SM (1) SMT202400214T1 (enExample)
TN (1) TN2015000086A1 (enExample)
TW (2) TWI694085B (enExample)
UY (2) UY35027A (enExample)
WO (1) WO2014043344A1 (enExample)
ZA (1) ZA201501457B (enExample)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3056568B1 (en) 2006-03-31 2021-09-15 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
CN101874042B9 (zh) 2007-09-26 2019-01-01 中外制药株式会社 利用cdr的氨基酸取代来改变抗体等电点的方法
CA2721052C (en) 2008-04-11 2023-02-21 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
EP2576615B1 (en) 2010-05-26 2016-03-30 Bristol-Myers Squibb Company Fibronectin based scaffold proteins having improved stability
CN103328632A (zh) 2010-11-30 2013-09-25 中外制药株式会社 与多分子的抗原重复结合的抗原结合分子
US9469676B2 (en) * 2011-04-13 2016-10-18 Bristol-Myers Squibb Company Fc fusion proteins comprising novel linkers or arrangements
WO2014030750A1 (ja) 2012-08-24 2014-02-27 中外製薬株式会社 マウスFcγRII特異的Fc抗体
WO2014030728A1 (ja) 2012-08-24 2014-02-27 中外製薬株式会社 FcγRIIb特異的Fc領域改変体
PL3564258T3 (pl) 2012-09-13 2021-10-25 Bristol-Myers Squibb Company Oparte na fibronektynie białka z domeną rusztowania, które wiążą się z miostatyną
ES2715710T3 (es) 2013-01-25 2019-06-05 Shire Human Genetic Therapies Folistatina en el tratamiento de la distrofía muscular de Duchenne
US20150361159A1 (en) 2013-02-01 2015-12-17 Bristol-Myers Squibb Company Fibronectin based scaffold proteins
EP2953968B1 (en) 2013-02-06 2018-07-25 Bristol-Myers Squibb Company Fibronectin type iii domain proteins with enhanced solubility
US10065987B2 (en) 2013-02-12 2018-09-04 Bristol-Myers Squibb Company High pH protein refolding methods
CN113621057A (zh) 2013-04-02 2021-11-09 中外制药株式会社 Fc区变体
PL2981822T3 (pl) 2013-05-06 2021-07-12 Scholar Rock, Inc. Kompozycje i sposoby modulacji czynnika wzrostu
ES2913840T3 (es) 2014-03-20 2022-06-06 Bristol Myers Squibb Co Dominios de tipo III de fibronectina de unión a seroalbúmina
WO2015143156A1 (en) 2014-03-20 2015-09-24 Bristol-Myers Squibb Company Stabilized fibronectin based scaffold molecules
WO2015161108A1 (en) * 2014-04-16 2015-10-22 The Scripps Research Institute Pparg modulators for treatment of osteoporosis
US11072681B2 (en) 2014-07-28 2021-07-27 The Regents Of The University Of California Compositions and methods of making polymerizing nucleic acids
WO2016023036A1 (en) 2014-08-08 2016-02-11 The Regents Of The University Of California High density peptide polymers
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
US11566082B2 (en) 2014-11-17 2023-01-31 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
KR20230125855A (ko) 2014-11-21 2023-08-29 브리스톨-마이어스 스큅 컴퍼니 Cd73에 대항한 항체 및 그의 용도
LT3221346T (lt) 2014-11-21 2020-11-10 Bristol-Myers Squibb Company Antikūnai, apimantys modifikuotas sunkiosios grandinės pastoviąsias sritis
KR102632418B1 (ko) 2014-11-25 2024-01-31 브리스톨-마이어스 스큅 컴퍼니 영상화를 위한 신규 pd-l1 결합 폴리펩티드
JP6701217B2 (ja) 2014-11-25 2020-05-27 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 生物学的製剤の１８ｆ−放射性標識方法および組成物
IL278014B2 (en) 2014-12-19 2023-10-01 Chugai Pharmaceutical Co Ltd Anti-myostatin antibodies, polypeptides containing variable FC regions and methods of use
CN110256558B (zh) 2014-12-23 2023-07-04 百时美施贵宝公司 针对tigit的抗体
SG10201907215QA (en) 2015-02-05 2019-09-27 Chugai Pharmaceutical Co Ltd Antibodies Comprising An Ion Concentration Dependent Antigen-Binding Domain, Fc Region Variants, Il-8-Binding Antibodies, And Uses Therof
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US10993993B2 (en) * 2015-05-28 2021-05-04 Immunoforge Co., Ltd. Pharmaceutical composition for treating muscle atrophy or sarcopenia including glucagon-like peptide (GLP-1) or GLP-1 receptor agonist
UY36687A (es) 2015-05-29 2016-11-30 Bristol Myers Squibb Company Una Corporación Del Estado De Delaware Anticuerpos contra ox40 y sus usos
EA201890162A1 (ru) 2015-06-29 2018-07-31 Бристол-Маерс Сквибб Компани Антитела к cd40 с повышенной агонистической активностью
WO2017040332A1 (en) * 2015-08-28 2017-03-09 University Of Massachusetts Quantifying net axonal transport in motor neuron pathologies
EP3353198B1 (en) * 2015-09-23 2020-06-17 Bristol-Myers Squibb Company Glypican-3binding fibronectin based scafflold molecules
KR20180073693A (ko) 2015-11-09 2018-07-02 브리스톨-마이어스 스큅 컴퍼니 Cho 세포에서 생산되는 폴리펩티드의 품질 속성을 조작하는 방법
EP3394098A4 (en) 2015-12-25 2019-11-13 Chugai Seiyaku Kabushiki Kaisha ANTI-MYOSTATIN ANTIBODIES AND METHODS OF USE
KR20220033522A (ko) 2016-03-04 2022-03-16 브리스톨-마이어스 스큅 컴퍼니 항-cd73 항체와의 조합 요법
EP4406550A3 (en) 2016-03-04 2024-10-16 The Rockefeller University Antibodies to cd40 with enhanced agonist activity
RU2613420C1 (ru) * 2016-04-13 2017-03-16 Сергей Михайлович Юдин Рекомбинантный белок Мио-ГСД, способ его получения, инъекционный препарат для повышения мышечной массы сельскохозяйственных животных, птицы и животных семейства псовых, а также способ использования препарата
JP7031934B2 (ja) 2016-05-11 2022-03-08 サイティバ・バイオプロセス・アールアンドディ・アクチボラグ 分離マトリックス
US10703774B2 (en) 2016-09-30 2020-07-07 Ge Healthcare Bioprocess R&D Ab Separation method
EP3455243B1 (en) 2016-05-11 2021-03-24 Cytiva BioProcess R&D AB Separation matrix
US10730908B2 (en) 2016-05-11 2020-08-04 Ge Healthcare Bioprocess R&D Ab Separation method
US10654887B2 (en) 2016-05-11 2020-05-19 Ge Healthcare Bio-Process R&D Ab Separation matrix
CN109311948B (zh) 2016-05-11 2022-09-16 思拓凡生物工艺研发有限公司 清洁和/或消毒分离基质的方法
US10889615B2 (en) 2016-05-11 2021-01-12 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
EP3455240B1 (en) 2016-05-11 2025-01-01 Cytiva BioProcess R&D AB Method of storing a separation matrix
WO2017210335A1 (en) 2016-06-01 2017-12-07 Bristol-Myers Squibb Company Imaging methods using 18f-radiolabeled biologics
CN109562195A (zh) 2016-06-01 2019-04-02 百时美施贵宝公司 用pd-l1结合多肽进行pet成像
JP2019528311A (ja) * 2016-08-03 2019-10-10 ネクストキュア インコーポレイテッド Ｌａｉｒシグナル伝達を調節するための組成物及び方法
CN109689099B (zh) 2016-08-05 2023-02-28 中外制药株式会社 用于预防或治疗il-8相关疾病的组合物
US12448411B2 (en) 2016-09-30 2025-10-21 Cytiva Bioprocess R&D Ab Separation method
CN110234334B (zh) 2016-12-05 2024-02-06 大塚制药株式会社 肌肉萎缩抑制组合物
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
TWI788340B (zh) 2017-04-07 2023-01-01 美商必治妥美雅史谷比公司 抗icos促效劑抗體及其用途
TWI897843B (zh) * 2017-05-03 2025-09-21 美商必治妥美雅史谷比公司 結合至肌肉生長抑制素以纖維連接蛋白為主之支架結構域蛋白質的穩定調配物
CN110719915A (zh) 2017-05-25 2020-01-21 百时美施贵宝公司 包含经修饰的重链恒定区的抗体
KR102813744B1 (ko) 2017-12-27 2025-05-28 브리스톨-마이어스 스큅 컴퍼니 항-cd40 항체 및 그의 용도
CA3082975A1 (en) * 2018-01-25 2019-08-19 I-Mab Biopharma Us Limited Anti-pd-l1 antibody and il-7 fusions
CN108593615A (zh) * 2018-05-02 2018-09-28 浠思（上海）生物技术有限公司 利用htrf一步法筛选pd1/pd-l1阻断剂的方法
JP7051656B2 (ja) 2018-09-28 2022-04-11 三菱重工コンプレッサ株式会社 タービンステータ、蒸気タービン、及び仕切板
JP7520003B2 (ja) 2018-11-16 2024-07-22 ブリストル－マイヤーズ スクイブ カンパニー 抗ｎｋｇ２ａ抗体およびその使用
EP3887397A1 (en) 2018-11-28 2021-10-06 Bristol-Myers Squibb Company Antibodies comprising modified heavy constant regions
KR20220151189A (ko) 2020-03-09 2022-11-14 브리스톨-마이어스 스큅 컴퍼니 증진된 효능제 활성을 갖는 cd40에 대한 항체
US20230192867A1 (en) 2020-05-15 2023-06-22 Bristol-Myers Squibb Company Antibodies to garp
US11566346B2 (en) * 2020-06-25 2023-01-31 Philip David Rodley Protein scaffold
BR112023008490A2 (pt) * 2020-11-20 2023-12-12 Zoetis Services Llc Variantes de anticorpo bovino
CN119562762A (zh) 2022-04-04 2025-03-04 加利福尼亚大学董事会 遗传互补组合物和方法
WO2025177263A1 (en) 2024-02-25 2025-08-28 Biohaven Therapeutics Ltd. Myostatin-binding proteins
WO2025219859A1 (en) 2024-04-14 2025-10-23 Biohaven Therapeutics Ltd. Combination therapy to treat overweight, obesity, and related health conditions

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010070094A1 (en) 2008-12-19 2010-06-24 Glaxo Group Limited Myostatin binding proteins
WO2011130354A1 (en) 2010-04-13 2011-10-20 Bristol-Myers Squibb Company Fibronectin based scaffold domain proteins that bind pcsk9
WO2011140086A2 (en) 2010-05-03 2011-11-10 Bristol-Myers Squibb Company Serum albumin binding molecules
WO2012088006A1 (en) 2010-12-22 2012-06-28 Bristol-Myers Squibb Company Fibronectin based scaffold domain proteins that bind il-23

Family Cites Families (113)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US5672502A (en) 1985-06-28 1997-09-30 Celltech Therapeutics Limited Animal cell culture
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
US5614492A (en) 1986-05-05 1997-03-25 The General Hospital Corporation Insulinotropic hormone GLP-1 (7-36) and uses thereof
US5514581A (en) 1986-11-04 1996-05-07 Protein Polymer Technologies, Inc. Functional recombinantly prepared synthetic protein polymer
US5770697A (en) 1986-11-04 1998-06-23 Protein Polymer Technologies, Inc. Peptides comprising repetitive units of amino acids and DNA sequences encoding the same
US5589173A (en) 1986-11-04 1996-12-31 Genentech, Inc. Method and therapeutic compositions for the treatment of myocardial infarction
US6018030A (en) 1986-11-04 2000-01-25 Protein Polymer Technologies, Inc. Peptides comprising repetitive units of amino acids and DNA sequences encoding the same
US5641648A (en) 1986-11-04 1997-06-24 Protein Polymer Technologies, Inc. Methods for preparing synthetic repetitive DNA
US6048728A (en) 1988-09-23 2000-04-11 Chiron Corporation Cell culture medium for enhanced cell growth, culture longevity, and product expression
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
JP3051145B2 (ja) 1990-08-28 2000-06-12 住友製薬株式会社 新規なポリエチレングリコール誘導体修飾ペプチド
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
US5506134A (en) 1990-10-22 1996-04-09 Corvas International, Inc. Hypridoma and monoclonal antibody which inhibits blood coagulation tissue factor/factor VIIa complex
US5792742A (en) 1991-06-14 1998-08-11 New York University Fibrin-binding peptide fragments of fibronectin
PT752248E (pt) 1992-11-13 2001-01-31 Idec Pharma Corp Aplicacao terapeutica de anticorpos quimericos e marcados radioactivamente contra antigenios de diferenciacao restrita de linfocitos b humanos para o tratamento do linfoma de celulas b
WO1994017097A1 (en) 1993-01-19 1994-08-04 Regents Of The University Of Minnesota Synthetic fibronectin fragments as inhibitors of retroviral infections
US7393682B1 (en) 1993-03-19 2008-07-01 The Johns Hopkins University School Of Medicine Polynucleotides encoding promyostatin polypeptides
WO1994021681A1 (en) 1993-03-19 1994-09-29 Johns Hopkins University School Of Medicine Growth differentiation factor-8
US20030074680A1 (en) 1993-03-19 2003-04-17 Johns Hopkins University School Of Medicine Growth differentiation factor-8
US5994618A (en) 1997-02-05 1999-11-30 Johns Hopkins University School Of Medicine Growth differentiation factor-8 transgenic mice
US6607884B1 (en) 1993-03-19 2003-08-19 The Johns Hopkins University School Of Medicine Methods of detecting growth differentiation factor-8
US6673534B1 (en) 1995-10-26 2004-01-06 The Johns Hopkins University School Of Medicine Methods for detection of mutations in myostatin variants
US6465239B1 (en) 1993-03-19 2002-10-15 The John Hopkins University School Of Medicine Growth differentiation factor-8 nucleic acid and polypeptides from aquatic species and non-human transgenic aquatic species
US7332575B2 (en) 1994-03-18 2008-02-19 The Johns Hopkins University School Of Medicine Growth differentiation factor-8 nucleic acid and polypeptide from aquatic species, and transgenic aquatic species
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
DE69835143T2 (de) 1997-01-21 2007-06-06 The General Hospital Corp., Boston Selektion von proteinen mittels rns-protein fusionen
US6261804B1 (en) 1997-01-21 2001-07-17 The General Hospital Corporation Selection of proteins using RNA-protein fusions
AU6274298A (en) 1997-02-05 1998-08-25 Johns Hopkins University School Of Medicine, The Growth differentiation factor-8
US7749498B2 (en) 1997-03-10 2010-07-06 Genentech, Inc. Antibodies for inhibiting blood coagulation and methods of use thereof
EP1958962A3 (en) 1997-06-12 2013-05-01 Novartis International Pharmaceutical Ltd. Artificial antibody polypeptides
WO1999051773A1 (en) 1998-04-03 1999-10-14 Phylos, Inc. Addressable protein arrays
AU765214B2 (en) 1998-05-06 2003-09-11 Metamorphix International, Inc. Methods for treating diabetes by inhibiting gdf-8
US7115396B2 (en) 1998-12-10 2006-10-03 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
AU775076B2 (en) 1998-12-10 2004-07-15 Bristol-Myers Squibb Company Protein scaffolds for antibody mimics and other binding proteins
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US20050287153A1 (en) 2002-06-28 2005-12-29 Genentech, Inc. Serum albumin binding peptides for tumor targeting
US20050019826A1 (en) 2000-03-31 2005-01-27 Roselyne Tournaire Peptides blocking vascular endothelial growth factor(vegf)-mediated angiogenesis, polynucleotides encoding said pepetides and methods of use thereof
WO2002004523A2 (en) 2000-07-11 2002-01-17 Research Corporation Technologies, Inc. Artificial antibody polypeptides
WO2002032925A2 (en) 2000-10-16 2002-04-25 Phylos, Inc. Protein scaffolds for antibody mimics and other binding proteins
US7598352B2 (en) 2000-11-17 2009-10-06 University Of Rochester Method of identifying polypeptide monobodies which bind to target proteins and use thereof
EP1383782A1 (en) 2001-03-26 2004-01-28 Sirna Therpeutics, Inc. Oligonucleotide mediated inhibition of hepatitis b virus and hepatitis c virus replication
US7556925B2 (en) 2001-04-04 2009-07-07 University Of Rochester ανβ3 integrin-binding polypeptide monobodies and their use
US7320789B2 (en) 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
WO2003104418A2 (en) 2002-06-06 2003-12-18 Research Corporation Technologies, Inc. Reconstituted polypeptides
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
US7261893B2 (en) 2002-10-22 2007-08-28 Wyeth Neutralizing antibodies against GDF-8 and uses therefor
PT2316852E (pt) 2002-11-08 2014-06-23 Ablynx Nv Anticorpos de domínio único estáveis
US20080220049A1 (en) 2003-12-05 2008-09-11 Adnexus, A Bristol-Myers Squibb R&D Company Compositions and methods for intraocular delivery of fibronectin scaffold domain proteins
BRPI0417302A (pt) 2003-12-05 2007-03-06 Compound Therapeutics Inc inibidores de receptores de fator de crescimento endotelial vascular do tipo 2
EP1729795B1 (en) 2004-02-09 2016-02-03 Human Genome Sciences, Inc. Albumin fusion proteins
JP4695133B2 (ja) 2004-03-23 2011-06-08 イーライ リリー アンド カンパニー 抗ミオスタチン抗体
WO2005118646A2 (en) 2004-04-26 2005-12-15 Centocor, Inc. Epitope directed selection of antibodies to murine tissue factor
CA2567520A1 (en) 2004-06-01 2005-12-15 Genentech, Inc. Maytansinoid-antibody conjugates
MX2007003789A (es) 2004-10-04 2007-07-20 Qlt Usa Inc Suministro ocular de formulaciones polimericas para suministro.
NZ538097A (en) 2005-02-07 2006-07-28 Ovita Ltd Method and compositions for improving wound healing
AP2007004243A0 (en) 2005-04-25 2007-12-31 Pfizer Antibodies to myostatin
SI1915397T1 (sl) 2005-08-19 2015-05-29 Wyeth Llc Antagonistična protitelesa proti GDF-8 in uporabe pri zdravljenju ALS in drugih obolenj, povezanih z GDF-8
WO2007044411A2 (en) 2005-10-06 2007-04-19 Eli Lilly And Company Anti-myostatin antibodies
UA92504C2 (en) 2005-10-12 2010-11-10 Эли Лилли Энд Компани Anti-myostatin monoclonal antibody
MX2008007324A (es) 2005-12-06 2009-03-04 Amgen Inc Usos de antagonistas de miostatina.
US20070269422A1 (en) 2006-05-17 2007-11-22 Ablynx N.V. Serum albumin binding proteins with long half-lives
HRP20130320T1 (en) 2006-09-05 2013-05-31 Eli Lilly And Company Anti-myostatin antibodies
WO2008031098A1 (en) 2006-09-09 2008-03-13 The University Of Chicago Binary amino acid libraries for fibronectin type iii polypeptide monobodies
CA2670471A1 (en) 2006-11-22 2008-06-05 Adnexus, A Bristol-Myers Squibb R&D Company (A Delaware Corporation) Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including igf-ir
WO2008097497A2 (en) 2007-02-02 2008-08-14 Adnexus, A Bristol-Myers Squibb R & D Company Vegf pathway blockade
EP2738257A1 (en) 2007-05-22 2014-06-04 Amgen Inc. Compositions and methods for producing bioactive fusion proteins
US8470966B2 (en) 2007-08-10 2013-06-25 Protelica, Inc. Universal fibronectin type III binding-domain libraries
US20090176654A1 (en) 2007-08-10 2009-07-09 Protelix, Inc. Universal fibronectin type III binding-domain libraries
US8680019B2 (en) 2007-08-10 2014-03-25 Protelica, Inc. Universal fibronectin Type III binding-domain libraries
US20100285000A1 (en) 2007-08-20 2010-11-11 Bristol-Myers Squibb Company Use of vegfr-2 inhibitors for treating metastatic cancer
KR100857861B1 (ko) 2007-10-15 2008-09-11 주식회사 바이오리더스 Ｍｙｏ－２ 펩타이드 중합체와 마이오스타틴의 융합단백질표면발현용 벡터 및 상기 벡터로 형질전환된 미생물
CN101932720A (zh) 2007-10-31 2010-12-29 米迪缪尼有限公司 蛋白质支架
PE20091163A1 (es) 2007-11-01 2009-08-09 Wyeth Corp Anticuerpos para gdf8
EP2217274A1 (en) 2007-11-28 2010-08-18 Bristol-Myers Squibb Company Combination vegfr2 therapy with mtor inhibitors
AU2008345674A1 (en) 2007-12-19 2009-07-09 Centocor, Ortho Biotech Inc. Alternative scaffold protein fusions phage display via fusion to pIX of M13 phage
CA2710835A1 (en) 2007-12-27 2009-07-09 Novartis Ag Improved fibronectin-based binding molecules and their use
EP2080812A1 (en) 2008-01-18 2009-07-22 Transmedi SA Compositions and methods of detecting post-stop peptides
JP2011517314A (ja) 2008-02-14 2011-06-02 ブリストル−マイヤーズ スクイブ カンパニー Ｅｇｆｒに結合する操作されたタンパク質に基づく標的化された治療薬
WO2009133208A1 (en) 2008-05-02 2009-11-05 Novartis Ag Improved fibronectin-based binding molecules and uses thereof
CN102099373A (zh) 2008-05-22 2011-06-15 百时美施贵宝公司 基于纤连蛋白的多价支架结构域蛋白
US8415291B2 (en) 2008-10-31 2013-04-09 Centocor Ortho Biotech Inc. Anti-TNF alpha fibronectin type III domain based scaffold compositions, methods and uses
RS55218B1 (sr) 2008-10-31 2017-02-28 Janssen Biotech Inc Kompozicije fibronektin tip iii skalno baziranih domena, metode i upotrebe
TWI496582B (zh) 2008-11-24 2015-08-21 必治妥美雅史谷比公司 雙重專一性之ｅｇｆｒ／ｉｇｆｉｒ結合分子
WO2010069913A1 (en) 2008-12-16 2010-06-24 Novartis Ag Yeast display systems
EP2396000A1 (en) 2009-02-11 2011-12-21 Bristol-Myers Squibb Company Combination vegfr2 therapy with temozolomide
MX2011008566A (es) 2009-02-12 2011-11-29 Janssen Biotech Inc Composiciones supercontigo basadas en el dominio de fibronectina tipo iii, metodos y usos.
US8067201B2 (en) 2009-04-17 2011-11-29 Bristol-Myers Squibb Company Methods for protein refolding
US20120270797A1 (en) 2009-08-13 2012-10-25 Massachusetts Institute Of Technology Engineered proteins including mutant fibronectin domains
WO2011051333A1 (en) 2009-10-30 2011-05-05 Novartis Ag Universal fibronectin type iii bottom-side binding domain libraries
WO2011051466A1 (en) 2009-11-02 2011-05-05 Novartis Ag Anti-idiotypic fibronectin-based binding molecules and uses thereof
US20110123545A1 (en) 2009-11-24 2011-05-26 Bristol-Myers Squibb Company Combination of vegfr2 and igf1r inhibitors for the treatment of proliferative diseases
WO2011092233A1 (en) 2010-01-29 2011-08-04 Novartis Ag Yeast mating to produce high-affinity combinations of fibronectin-based binders
CA2788972A1 (en) 2010-02-12 2011-08-18 University Of Rochester Antigenic mimics of discontinuous epitopes of pathogen recognized by broadly neutralizing antibodies
US8927693B2 (en) 2010-02-18 2015-01-06 Bristol-Myers Squibb Company Fibronectin based scaffold domain proteins that bind IL-23
JP2013523179A (ja) 2010-04-13 2013-06-17 メディミューン，エルエルシー フィブロネクチンタイプｉｉｉドメインに基づく多量体足場
RU2767543C2 (ru) 2010-04-30 2022-03-17 Янссен Байотек, Инк. Композиции на основе стабилизированных фибронектиновых доменов, способы и области их применения
JO3340B1 (ar) 2010-05-26 2019-03-13 Regeneron Pharma مضادات حيوية لـعامل تمايز النمو 8 البشري
EP2576615B1 (en) 2010-05-26 2016-03-30 Bristol-Myers Squibb Company Fibronectin based scaffold proteins having improved stability
JP6092773B2 (ja) 2010-07-30 2017-03-08 ノバルティス アーゲー フィブロネクチンクレードル分子及びそのライブラリ
SG10201506405YA (en) 2010-08-16 2015-10-29 Amgen Inc Polypeptides That Bind Myostatin, Compositions And Methods
US9469676B2 (en) 2011-04-13 2016-10-18 Bristol-Myers Squibb Company Fc fusion proteins comprising novel linkers or arrangements
ES2848531T3 (es) 2011-05-17 2021-08-10 Bristol Myers Squibb Co Métodos mejorados para la selección de proteínas de unión
US20140187488A1 (en) 2011-05-17 2014-07-03 Bristol-Myers Squibb Company Methods for maintaining pegylation of polypeptides
US9200273B2 (en) 2011-09-27 2015-12-01 Janssen Biotech, Inc. Fibronectin type III repeat based protein scaffolds with alternative binding surfaces
US9453080B2 (en) 2012-06-11 2016-09-27 Amgen Inc. Dual receptor antagonistic antigen-binding proteins and uses thereof
KR101704893B1 (ko) 2012-06-15 2017-02-08 화이자 인코포레이티드 Gdf-8에 대한 개선된 길항물질 항체 및 그의 용도
PL3564258T3 (pl) 2012-09-13 2021-10-25 Bristol-Myers Squibb Company Oparte na fibronektynie białka z domeną rusztowania, które wiążą się z miostatyną
TWI897843B (zh) 2017-05-03 2025-09-21 美商必治妥美雅史谷比公司 結合至肌肉生長抑制素以纖維連接蛋白為主之支架結構域蛋白質的穩定調配物

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010070094A1 (en) 2008-12-19 2010-06-24 Glaxo Group Limited Myostatin binding proteins
WO2011130354A1 (en) 2010-04-13 2011-10-20 Bristol-Myers Squibb Company Fibronectin based scaffold domain proteins that bind pcsk9
WO2011140086A2 (en) 2010-05-03 2011-11-10 Bristol-Myers Squibb Company Serum albumin binding molecules
WO2012088006A1 (en) 2010-12-22 2012-06-28 Bristol-Myers Squibb Company Fibronectin based scaffold domain proteins that bind il-23

Also Published As

Publication number Publication date
US8933199B2 (en) 2015-01-13
CL2015000500A1 (es) 2015-07-31
EP4397675A3 (en) 2024-10-16
MY172863A (en) 2019-12-13
US11813315B2 (en) 2023-11-14
CN108409856B (zh) 2022-03-04
CN104768969B (zh) 2021-04-16
KR102424590B1 (ko) 2022-07-27
IL237559A0 (en) 2015-04-30
TWI694085B (zh) 2020-05-21
UY35027A (es) 2014-03-31
EP4397675A2 (en) 2024-07-10
PL2895503T3 (pl) 2019-09-30
JP2018183138A (ja) 2018-11-22
LT2895503T (lt) 2019-07-25
CA2884730C (en) 2023-07-04
CN104768969A (zh) 2015-07-08
CN108409856A (zh) 2018-08-17
NZ800822A (en) 2025-02-28
US10406212B2 (en) 2019-09-10
BR112015005466B1 (pt) 2023-04-11
HUE054699T2 (hu) 2021-09-28
DK3564258T3 (da) 2021-06-21
DK2895503T3 (da) 2019-05-27
ES2727453T3 (es) 2019-10-16
EA033536B1 (ru) 2019-10-31
EP3564258B1 (en) 2021-04-28
JP2015530390A (ja) 2015-10-15
US20170088602A1 (en) 2017-03-30
ES2984405T3 (es) 2024-10-29
US9493546B2 (en) 2016-11-15
LT3835310T (lt) 2024-04-25
KR102187714B1 (ko) 2020-12-07
MX366666B (es) 2019-07-19
EP3835310B1 (en) 2024-03-20
EP2895503A1 (en) 2015-07-22
EA201590543A1 (ru) 2015-06-30
SMT202400214T1 (it) 2024-07-09
IL294314A (en) 2022-08-01
US20140107020A1 (en) 2014-04-17
SG11201501741YA (en) 2015-04-29
EP3564258A1 (en) 2019-11-06
SI3835310T1 (sl) 2024-07-31
SI2895503T1 (sl) 2019-08-30
AU2018201273B2 (en) 2020-04-09
SI3564258T1 (sl) 2021-07-30
PT2895503T (pt) 2019-06-03
US20140105896A1 (en) 2014-04-17
PL3835310T3 (pl) 2024-06-03
HRP20210990T1 (hr) 2021-09-17
PE20150954A1 (es) 2015-06-20
HUE043482T2 (hu) 2019-08-28
TWI633117B (zh) 2018-08-21
US20150231211A1 (en) 2015-08-20
PT3835310T (pt) 2024-05-20
US20170354718A1 (en) 2017-12-14
RS62009B1 (sr) 2021-07-30
EP3835310A1 (en) 2021-06-16
PH12015500397A1 (en) 2015-04-27
JP6346895B2 (ja) 2018-06-20
US10245302B2 (en) 2019-04-02
CA2884730A1 (en) 2014-03-20
HK1212717A1 (en) 2016-06-17
HUE067383T2 (hu) 2024-10-28
IL270110B (en) 2022-08-01
IL270110A (enExample) 2019-12-31
FI3835310T3 (fi) 2024-05-31
HRP20190845T1 (hr) 2019-08-09
TN2015000086A1 (en) 2016-06-29
MX390017B (es) 2025-03-11
KR20150054938A (ko) 2015-05-20
RS65556B1 (sr) 2024-06-28
AU2018201273A1 (en) 2018-03-15
MX2015002894A (es) 2015-06-03
PL3564258T3 (pl) 2021-10-25
US20240316161A1 (en) 2024-09-26
EP2895503B1 (en) 2019-03-27
US20190307855A1 (en) 2019-10-10
MX2019008391A (es) 2019-09-09
KR20200138435A (ko) 2020-12-09
AU2013315482B2 (en) 2018-03-15
RS58801B1 (sr) 2019-07-31
TW201823269A (zh) 2018-07-01
SG10201701970TA (en) 2017-05-30
WO2014043344A1 (en) 2014-03-20
US8993265B2 (en) 2015-03-31
ZA201501457B (en) 2021-09-29
LT3564258T (lt) 2021-08-25
HRP20240676T1 (hr) 2024-10-11
BR112015005466A2 (pt) 2017-08-08
US20150072919A1 (en) 2015-03-12
KR20220107082A (ko) 2022-08-01
US8853154B2 (en) 2014-10-07
NZ628446A (en) 2017-06-30
JP6793680B2 (ja) 2020-12-02
UY40128A (es) 2023-04-28
TW201416376A (zh) 2014-05-01
US9662373B2 (en) 2017-05-30
DK3835310T3 (da) 2024-06-03
AU2013315482A1 (en) 2015-03-12
IL237559B (en) 2019-10-31
PH12015500397B1 (en) 2021-02-19
US20140309163A1 (en) 2014-10-16
PT3564258T (pt) 2021-06-30
MY189682A (en) 2022-02-25
SG10201913685YA (en) 2020-03-30
ES2879387T3 (es) 2021-11-22

Similar Documents

Publication Publication Date Title
KR102751864B1 (ko) 미오스타틴에 결합하는 피브로넥틴 기반 스캐폴드 도메인 단백질
HK40107892A (en) Fibronectin based scaffold domain proteins that bind to myostatin
HK40055226B (en) Fibronectin based scaffold domain proteins that bind to myostatin
HK40055226A (en) Fibronectin based scaffold domain proteins that bind to myostatin
HK1212717B (en) Fibronectin based scaffold domain proteins that bind to myostatin

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20220720

Application number text: 1020207034555

Filing date: 20201201

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20220819

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230408

Patent event code: PE09021S01D

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

Comment text: Final Notice of Reason for Refusal

Patent event date: 20231018

Patent event code: PE09021S02D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20241008

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20250103

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20250103

End annual number: 3

Start annual number: 1

PG1601 Publication of registration